The acceleration of drug and medical device development has become a major strategic priority in a context marked by increasing pressure on timelines, costs and patient access to innovation. Among the methodological approaches frequently highlighted in scientific and regulatory discussions, adaptive clinical trials are gaining increasing attention.
Often presented as more flexible and more efficient than traditional trial designs, adaptive clinical trials nevertheless raise a central question: are they truly applicable in practice within the European regulatory framework, both for medicines and for medical devices?
Adaptive clinical trials: what are we really talking about?
Adaptive clinical trials are trials in which certain predefined parameters may be modified during the study based on planned interim analyses. These adaptations rely on several core principles:
- stepwise authorisation approaches, beginning with a restricted patient population and potentially expanding to broader populations;
- confirmation of the benefit–risk profile following a conditional authorisation based on preliminary data (often using surrogate endpoints considered predictive of meaningful clinical outcomes);
- collection of real-world data to complement traditional clinical trial evidence;
- early involvement of patients and health technology assessment (HTA) bodies in discussions regarding development strategies.
It is essential to emphasise that, from a regulatory perspective, adaptation can never be improvised. All adaptation rules must be pre-specified in the protocol, and modifications are generally based on the analysis of interim data collected during the trial.
This requirement is clearly highlighted by the European Medicines Agency (EMA), which frames the use of adaptive designs in its methodological guidelines.
Why such strong interest in adaptive clinical trials?
The growing interest in adaptive clinical trials is based on several widely shared observations:
- increasing protocol complexity,
- difficulties in recruiting specific patient populations,
- high scientific uncertainty in early phases,
- the need to limit patient exposure to ineffective strategies.
The concept therefore applies particularly to treatments in therapeutic areas characterised by significant unmet medical needs and where traditional data collection pathways may be difficult.
From a theoretical perspective, adaptive clinical trials allow for more efficient allocation of resources, better exploitation of interim data and, in certain cases, faster decision-making.
These advantages explain their growing use in oncology, rare diseases and areas of rapid therapeutic innovation.
What regulatory authorities accept… and what they do not
Contrary to common assumptions, European and international regulatory authorities do not reject adaptive clinical trials in principle. However, their acceptability is strictly conditioned.
The European Medicines Agency emphasises several key requirements:
- strict control of statistical biases associated with interim analyses;
- full traceability and pre-specification of adaptation decisions;
- clear separation between operational trial teams and independent structures responsible for interim analyses;
- robust scientific justification for any design modification.
Source:
https://www.ema.europa.eu
Regulators insist that adaptive flexibility must never compromise the integrity of the data, the control of type I error, or the reliability of conclusions regarding efficacy and safety.
Expected benefits of adaptive clinical trials
Conceptually, adaptive clinical trials offer several potential advantages:
- earlier discontinuation of ineffective treatment strategies;
- reduced exposure of patients to non-beneficial interventions;
- improved statistical efficiency;
- optimisation of exploratory development phases.
By allowing adjustments in sample size, randomisation ratios or treatment arms, adaptive clinical trials may contribute to a more dynamic and responsive development process.
However, these methodological advantages come with important limitations:
- risks of statistical or operational bias;
- challenges in ensuring data integrity;
- potential reduction in statistical power due to multiple interim comparisons;
- increased complexity in operational execution and data monitoring.
The implementation of adaptive clinical trials therefore requires highly specialised expertise in biostatistics, data monitoring and regulatory strategy.
And what about medical devices?
While adaptive clinical trials have historically been associated with medicinal product development, the question also arises for medical devices, particularly since the entry into application of Regulation (EU) 2017/745 (MDR).
The U.S. Food and Drug Administration (FDA) has issued specific guidance on adaptive designs in clinical investigations conducted for medical devices.
In practice, adaptive designs in medical device investigations may allow modifications during the study of elements such as:
- sample size;
- eligibility criteria;
- randomisation procedures;
- evaluation endpoints.
Source:
https://www.multihealthgroup.com
However, the regulatory landscape differs between medicines and devices. Under the MDR, clinical investigations must demonstrate safety and performance within a lifecycle-based approach, often complemented by Post-Market Clinical Follow-up (PMCF).
Adaptive clinical trials may therefore represent an opportunity for innovative devices, provided that methodological rigor and regulatory anticipation are fully ensured.
Conclusion: a real promise, but under strict conditions
Adaptive clinical trials represent a significant methodological advancement for both medicinal products and medical devices. They offer promising perspectives for optimising clinical development, particularly in areas characterised by high uncertainty or unmet medical need.
However, their value depends entirely on the conditions of implementation. Adaptive designs must be embedded within a scientifically robust framework, operationally controlled and regulatorily anticipated.
The key issue is therefore not whether adaptive clinical trials are desirable, but under which conditions they genuinely create value without compromising data quality, statistical validity or the confidence of regulatory authorities and patients.
In a European regulatory environment that emphasises methodological rigour and transparency, adaptive clinical trials can be powerful tools—provided they are designed, justified and governed with the highest level of scientific discipline.
